|
LigaChem Biosciences is a biotechnology company focused on the research and development of novel therapeutics, primarily in the areas of antibody-drug conjugates (ADCs), synthetic small molecules, and immunotherapy. The company develops its proprietary ADC platform technology, ConjuALL, which utilizes unique linkers and payloads to target cancer cells. Its pipeline includes multiple ADC candidates such as LCB14 (HER2), LCB71 (ROR1), LCB84 (TROP2), and LCB97 (L1CAM), which are in various stages of clinical trials or have been licensed out to global partners including Janssen, Ono Pharma, CStone, and Iksuda. In addition to its R&D business, the company operates a medical business segment that supplies medical devices and consumables to hospitals in the Seoul metropolitan area. LigaChem Biosciences collaborates with international pharmaceutical companies through technology transfer, co-development, and licensing agreements to advance its drug candidates toward commercialization. Summarised from the company's own disclosures, fiscal year ended Mar 2026 |
Industry Biotechnology | Homepage ligachembio.com |
| Sector Healthcare | IR page ligachembio.com | |
|
Tags
antibody-drug conjugates, immunotherapy, synthetic small molecules, oncology, antibiotics, medical devices, medical consumables, technology transfer, drug discovery, ConjuALL, LCB14, LCB71, LCB84, LCB97, LCB02A, LCB43, Caxmotabart Entudotin, CS5001, Iksuda, Janssen, Ono Pharma, CStone, Fosun Pharma, AntibodyChem Biosciences, Bascan Biopharmaceuticals
|
Press page — |
Metrics
| Valuation | |
|---|---|
| Market cap | ₩ 3.152T |
| Market cap (USD) | $ 2.32B |
| P/E | -17.61 |
| PEG | — |
| P/BV | 7.88 |
| P/S | 31.91 |
| P/OCF | -16.45 |
| P/FCF | -16.20 |
| Dividend yield | — |
| Turnover / mcap | — |
| Returns | |
|---|---|
| ROE | -16.3% |
| ROI | -18.0% |
| ROIC | -15.7% |
| Profit margin | -64.7% |
| Growth | |
|---|---|
| Revenue growing | Yes |
| Profits growing | No |
| Revenue up 3y | — |
| Revenue up 5y | — |
| Earnings growth 3y (net profit CAGR) | — |
| Quality | |
|---|---|
| Profitable | No |
| Margin expanding | No |
| Buying back stock | — |
| Diluting (TTM) | — |
| Debt/Equity | — |
| Podcast bulls (TTM) | Sign up |
| Podcast bears (TTM) | Sign up |
| Podcast sentiment (TTM) | Sign up |
| Podcast sentiment % (TTM) | Sign up |
| News sentiment (TTM) | — |
| Quality score | -69.2% |
| Insiders | |
|---|---|
| Buys, 1w | Sign up |
| Buys, 1m | Sign up |
| Buys, 1y | Sign up |
| Sells, 1w | Sign up |
| Sells, 1m | Sign up |
| Sells, 1y | Sign up |
Sign up to see this company's insider trades
| Figure | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 | FY 2014 | FY 2013 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 141.553B | — | — | — | — | 49.394B | 57.5B | 25.24B | 22.057B | 16.655B | 1.788B | 870.054M | 839.825M |
| Net profit | -91.552B | 7.8B | -73.704B | -45.092B | -23.391B | -6.986B | 13.586B | -25.77B | -12.934B | -14.725B | -8.237B | -8.686B | -5.835B |
| Free cash flow | -127.582B | 75.849B | -63.555B | -11.3B | -60.358B | -18.508B | 20.743B | -16.515B | -10.412B | -17.281B | -9.145B | -8.173B | -7.314B |
Filed figures
Lines the statements and their notes report beside the headline figures, read from the filings' XBRL as filed (no restatement applied), with figures computed from one filing's own lines. Cash-flow lines carry their cash direction: an outflow is negative. Each period links to its filing; a figure's period, report date and tag are in its tooltip.
| Figure | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Balance sheet detail | ||||||||||
| Trade receivables (KRW) | 12.6B | 15.5B | 17.7B | 11.1B | 20.6B | 22.5B | 12.8B | 14.8B | 13.7B | 11.8B |
| ↳ YoY growth | +36.7% | +23.6% | +13.8% | -37.1% | +85.0% | +9.2% | -43.1% | +15.9% | -7.4% | -14.3% |
| ↳ 5y CAGR | +100.2% | +172.2% | +17.5% | +12.3% | -3.8% | -3.5% | +4.3% | -10.6% | ||
| Borrowings, current (KRW) | 6.17B | 6.7B | — | 0.00 | — | 2.7B | 11.8B | 11.8B | 0.00 | 0.00 |
| Borrowings, non-current (KRW) | 7.85B | 8.52B | 0.00 | 1.9B | 3.61B | 9.15B | 0.00 | 0.00 | — | — |
| Bonds payable (KRW) | 14B | 15.2B | — | 0.00 | — | — | — | — | — | — |
| Lease liabilities (KRW) | — | — | 0.00 | 285M | 375M | 422M | 402M | 797M | 820M | 2.75B |
| Cash and deposits (KRW) | 2.97B | 8.62B | 10.2B | 66.9B | 54.6B | 140B | 118B | 63.1B | 129B | 98.6B |
| Intangible assets (KRW) | 26.8B | — | — | — | — | 8.6B | 7.89B | 6.9B | 8.44B | 104B |
| Net debt (borrowings + leases - cash) (KRW) | 4.89B | 6.6B | -10.2B | -65B | -50.7B | -128B | -106B | -50.4B | -128B | -95.9B |
| Cash flow detail | ||||||||||
| Operating cash flow (KRW) | -13B | -8.21B | -12.8B | 24.1B | -14.9B | -42B | -7.14B | -62.2B | 78.5B | -125B |
| Purchases of property, plant and equipment (KRW) | -4.24B | -2.2B | -3.76B | -3.37B | -3.61B | -18.3B | -4.16B | -1.32B | -2.63B | -3.05B |
| Purchases of intangible assets (KRW) | — | -342M | -213M | -121M | -480M | -294M | -608M | -883M | -3.07B | -2.99B |
| Share buybacks (cash effect) (KRW) | — | — | — | — | — | 0.00 | 0.00 | -4.88B | -20B | -7B |
| Interest paid (cash effect) (KRW) | -307M | -119M | -93.6M | 0.00 | -37.1M | -51.9M | -288M | -499M | -547M | -468M |
| Income taxes paid (cash effect) (KRW) | -37.8M | -14.5M | -66.6M | -504M | 37.7M | -82.1M | -386M | -1.09B | -5.94B | -8.52B |
| Free cash flow (OCF - PPE - intangibles) (KRW) | -17.3B | -10.8B | -16.7B | 20.6B | -19B | -60.7B | -11.9B | -64.4B | 72.8B | -131B |
| Income detail | ||||||||||
| Research and development expense (KRW) | — | — | — | — | — | — | — | 79.6B | 113B | 217B |
| Total comprehensive income (KRW) | -14.8B | -12.8B | -25.8B | 9.8B | -4.16B | -24B | -45.7B | -74.2B | 6.47B | -71.4B |
| Comprehensive income to owners (KRW) | -14.8B | -85.4M | -25.5B | 10.9B | — | — | — | -74.2B | 6.47B | -55.2B |
| Reported | Mar 29, 2019 | Mar 29, 2019 | May 31, 2021 | May 31, 2021 | May 31, 2021 | Mar 21, 2024 | Mar 21, 2024 | Mar 23, 2026 | Mar 23, 2026 | Mar 23, 2026 |
Sign up to see institutional holdings
Sign UpPodcast Mentions
Sign up to see podcast mentions and sentiment
Sign UpDisclosures filed with DART (material events and exchange disclosures), newest first, headlines as filed in Korean. The link opens the filing on DART. Press releases from the company's own website, newest first.
2026-10-28
Prompts
Click prompts to add them under the company line, click again to take one out, then copy the result into your AI chat. Shared by Asian Century Stocks and Uncovered Thai Stocks. Thank you.
ETFs Holding LCB
Exchange-traded funds whose newest published daily portfolio holds one of the company's listings, largest weight first.